SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-024530
Filing Date
2024-05-21
Accepted
2024-05-21 16:03:46
Documents
14
Period of Report
2024-05-17
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prme-20240517.htm   iXBRL 8-K 28157
2 EX-3.1 a05-21x2024xamendedaoi.htm EX-3.1 147118
  Complete submission text file 0001628280-24-024530.txt   339030

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20240517.xsd EX-101.SCH 1919
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20240517_lab.xml EX-101.LAB 23434
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20240517_pre.xml EX-101.PRE 13590
17 EXTRACTED XBRL INSTANCE DOCUMENT prme-20240517_htm.xml XML 3012
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41536 | Film No.: 24969241
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)